Silverberg, JI; Wollenberg, A; Legat, FJ; Laquer, VT; Ulianov, L; Cheong, SY; Ryzhkova, A; Piketty, C.
Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)
BRIT J DERMATOL. 2024; 191:
Doi: 10.1093/bjd/ljae266.042
[Poster]
Web of Science
FullText
FullText_MUG